Document Detail

Natural killer cell lymphoma in a pediatric patient with inflammatory bowel disease.
MedLine Citation:
PMID:  20837584     Owner:  NLM     Status:  MEDLINE    
Tumor necrosis factor α (TNF-α) antibody agents are an effective therapy for the treatment of inflammatory bowel disease (IBD); however, because of the potential for immune suppression with these drugs, TNF-α antibody agents can increase the risk of malignancy. We report here the case of an 11-year-old boy who presented with bowel obstruction. He also had a history of periodic fever, aphthous stomatitis, and cervical adenitis (PFAPA). Intestinal inflammation continued and impaired his quality of life; he was diagnosed with IBD of an undetermined type (IBD-U). Symptoms improved with infliximab, but he developed elevated transaminase levels with hepatosplenomegaly 1 year after scheduled infusions. Skin biopsy revealed an atypical lymphoid infiltrate consistent with an Epstein-Barr virus (EBV)-positive natural killer (NK)/T-cell lymphoma with associated hemophagocytic lymphohistiocytosis. Bone marrow biopsy revealed a similar EBV-positive lymphoid infiltrate consistent with an NK/T-cell lymphoma. EBV-positive tissue was present in gastrointestinal biopsies. Flow-cytometric analysis revealed an atypical, clonal NK-cell population, and biopsy specimens from several tissue sites tested positive for CD3, CD56, and CD30. The patient died soon after the diagnosis was made. This patient developed an EBV-driven malignancy while receiving infliximab. All patients with IBD who receive infliximab should be monitored for malignancy, especially young patients. This case underscores the need for future studies to better understand the biology of lymphoproliferative disorders.
Mark Deneau; Jeremy Wallentine; Stephen Guthery; Molly O'Gorman; John Bohnsack; Mark Fluchel; John Bezzant; John F Pohl
Related Documents :
19032754 - Induction of galectin-1 expression by htlv-i tax and its impact on htlv-i infectivity.
3037684 - Expression of cr1 and cr2 complement receptors following epstein-barr virus infection o...
8522314 - Ki-1 (cd30) positive anaplastic large cell lymphoma of t-cell phenotype developing in a...
2821654 - A human-human hybridoma producing cytotoxic antibody to hla-b15, cross-reacting with b1...
1678354 - The effects of interleukin 7 (il-7) on human bone marrow in vitro.
1717164 - Monocyte-induced down-modulation of cd16 and cd56 antigens on human natural killer cell...
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2010-09-13
Journal Detail:
Title:  Pediatrics     Volume:  126     ISSN:  1098-4275     ISO Abbreviation:  Pediatrics     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-05     Completed Date:  2010-10-27     Revised Date:  2013-08-23    
Medline Journal Info:
Nlm Unique ID:  0376422     Medline TA:  Pediatrics     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e977-81     Citation Subset:  AIM; IM    
Department of Pediatric Gastroenterology, Primary Children's Hospital, University of Utah, 100 N Mario Capecchi Dr, Suite 2650, Salt Lake City, UT 84113-1103, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / adverse effects,  therapeutic use
Gastrointestinal Agents / adverse effects,  therapeutic use
Inflammatory Bowel Diseases / complications*,  drug therapy*
Lymphoma, Extranodal NK-T-Cell / complications*,  diagnosis
Tumor Necrosis Factor-alpha / immunology
Grant Support
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Gastrointestinal Agents; 0/Tumor Necrosis Factor-alpha; 0/infliximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pediatric Clinical Research Networks: Current Status, Common Challenges, and Potential Solutions.
Next Document:  Helmet Versus Active Repositioning for Plagiocephaly: A Three-Dimensional Analysis.